Affordable Access

Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials.

Authors
  • Davidson, B L
  • Büller, H R
  • Decousus, H
  • Gallus, A
  • Gent, M
  • Piovella, F
  • Prins, M H
  • Raskob, G E
  • Segers, A E M
  • Lensing, A W A
Type
Published Article
Journal
Journal of thrombosis and haemostasis : JTH
Publication Date
Jun 01, 2007
Volume
5
Issue
6
Pages
1191–1194
Identifiers
PMID: 17403087
Source
Medline
License
Unknown

Abstract

The current recommended doses of fondaparinux and heparins for the treatment of venous thromboembolism appear to provide similar protection against recurrence and major bleeding to one another and to obese and non-obese patients.

Report this publication

Statistics

Seen <100 times